HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): James S. Tweddell Kathleen A. Mussatto Michael E. Mitchell Nancy S. Ghanayem Rammohan Marla Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tweddell, J. S. Articles by Hoffman, G. M. Search for Related Content PubMed PubMed Citation Articles by Tweddell, J. S. Articles by Hoffman, G. M. Related Collections Congenital - cyanotic

---

Original Articles: Pediatric Cardiac

Fontan Palliation in the Modern Era: Factors Impacting Mortality and Morbidity

Division of Cardiothoracic Surgery, Department of Surgery, Sections of Pediatric Cardiology and Critical Care, Departments of Pediatrics and Quantitative Health Sciences, Medical College of Wisconsin and Herma Heart Center, Children's Hospital of Wisconsin, Milwaukee, Wisconsin

Accepted for publication May 21, 2009.

^_* Address correspondence to Dr Tweddell, MS 715, Children's Hospital of Wisconsin, 9000 W Wisconsin Ave, Milwaukee, WI 53226 (Email: jtweddell{at}chw.org).

Presented at the Fifty-fifth Annual Meeting of the Southern Thoracic Surgical Association, Austin, TX, Nov 5–8, 2008.

Background: Advances in management of the Fontan patient include interval superior cavopulmonary shunt, total cavopulmonary connection, either lateral tunnel or extracardiac conduit, and the use of a fenestration. Coincident with these improvements, Fontan palliation has been applied to a wider ranger of anatomic subgroups.

Methods: A cross-sectional analysis of 256 consecutive patients undergoing a total cavopulmonary connection Fontan after superior cavopulmonary shunt between January 1, 1994, and June 30, 2007 were studied. Fenestration was used selectively. Fontan failure was defined as death, transplant, or takedown. Event-free survival was defined as freedom from death, transplant, Fontan takedown, functional class III to IV, pacemaker, antiarrhythmic medication, protein-losing enteropathy, stroke, or thrombus.

Results: Survival was 97% ± 1%, 96% ± 1%, and 94% ± 2%, respectively, at 1, 5, and 10 years. Event-free survival was 96% ± 1%, 87% ± 3%, and 64% ± 6%, respectively, at 1, 5, and 10 years. Factors predicting worse event-free survival included longer cross-clamp time (p = 0.003), fenestration (p = 0.014), and longer hospital length of stay (p = 0.016). Ventricular morphology did not predict outcome. Left ventricle (n = 113, 44%) versus right ventricle (n = 142, 56%) failure-free survival (death, transplant, or Fontan takedown) at 10 years was 92% ± 4% versus 91% ± 3%, respectively (p = 0.19). Left ventricle versus right ventricle event-free survival at 10 years was 75% ± 7% versus 67% ± 9%, respectively (p > 0.1).

Conclusions: Survival for patients undergoing a completion Fontan in the current era is excellent, but patients remain at risk for morbid events. In the intermediate follow-up period, we could not identify a difference in outcome between dominant left and right ventricle morphology.

This article has been cited by other articles:

				P. Monagle, A. K. C. Chan, N. A. Goldenberg, R. N. Ichord, J. M. Journeycake, U. Nowak-Gottl, and S. K. Vesely Antithrombotic Therapy in Neonates and Children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest, February 1, 2012; 141(2_suppl): e737S - e801S. [Abstract] [Full Text] [PDF]

				C. L. Brosig Commentary: The Use of Health and Behavior Codes in a Pediatric Cardiology Setting J. Pediatr. Psychol., January 19, 2012; (2012) jsr125v1. [Full Text] [PDF]

				P. Monagle, A. Cochrane, R. Roberts, C. Manlhiot, R. Weintraub, B. Szechtman, M. Hughes, M. Andrew, B. W. McCrindle, and Fontan Anticoagulation Study Group A Multicenter, Randomized Trial Comparing Heparin/Warfarin and Acetylsalicylic Acid as Primary Thromboprophylaxis for 2 Years After the Fontan Procedure in Children J. Am. Coll. Cardiol., August 2, 2011; 58(6): 645 - 651. [Abstract] [Full Text] [PDF]

				C. E. Canter Preventing Thrombosis After the Fontan Procedure: Not There Yet J. Am. Coll. Cardiol., August 2, 2011; 58(6): 652 - 653. [Full Text] [PDF]

				M. C. Wallace, J. Jaggers, J. S. Li, M. L. Jacobs, J. P. Jacobs, D. K. Benjamin, S. M. O'Brien, E. D. Peterson, P. B. Smith, and S. K. Pasquali Center Variation in Patient Age and Weight at Fontan Operation and Impact on Postoperative Outcomes Ann. Thorac. Surg., May 1, 2011; 91(5): 1445 - 1452. [Abstract] [Full Text] [PDF]

				S. Kutty, M. A. Frommelt, D. A. Danford, and J. S. Tweddell Medium-Term Outcomes of Kawashima and Completion Fontan Palliation in Single-Ventricle Heart Disease With Heterotaxy and Interrupted Inferior Vena Cava Ann. Thorac. Surg., November 1, 2010; 90(5): 1609 - 1613. [Abstract] [Full Text] [PDF]

				T. Sakurai, H. Kado, T. Nakano, K. Hinokiyama, S. Oda, J. Sugiura, T. Ushijima, and Y. Ueda The impact of extracardiac conduit-total cavopulmonary connection on apicocaval juxtaposition Eur J Cardiothorac Surg, October 1, 2010; 38(4): 439 - 444. [Abstract] [Full Text] [PDF]

				T. D. Simon, J. Berry, C. Feudtner, B. L. Stone, X. Sheng, S. L. Bratton, J. M. Dean, and R. Srivastava Children With Complex Chronic Conditions in Inpatient Hospital Settings in the United States Pediatrics, October 1, 2010; 126(4): 647 - 655. [Abstract] [Full Text] [PDF]

				S. Sathanandam, A. C. Polimenakos, C. Blair, C. El Zein, and M. N. Ilbawi Hypoplastic Left Heart Syndrome: Feasibility Study for Patients Undergoing Completion Fontan at or Prior to Two Years of Age Ann. Thorac. Surg., September 1, 2010; 90(3): 821 - 829. [Abstract] [Full Text] [PDF]